Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] APL is engaged in manufacturing and exporting pharmaceutical formulations and nutraceutical products. It caters to various domestic and global customers with tailor made products. It also engaged third party contract manufacturers for certain critical products. The company posted growth in its top and bottom lines for the reported periods. However, sudden boost in bottom lines from FY25 onwards raise eyebrows and concern over its sustainability. It is operating in a highly competitive and fragmented segment. Small equity base post-IPO indicates longer gestation period for migration. Well-informed/cash surplus investors may park moderate fund for long term. Read detail review...
Asston Pharmaceuticals Limited peer comparison with similar listed entities. (As on March 31, 2025)
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Asston Pharmaceuticals Limited | 6.90 | 6.90 | 17.09 | 40.36 | Standalone | ||
| Shelter Pharma Ltd | 6.26 | 6.26 | 36.96 | 6.70 | 16.94 | 1.14 | Standalone |
| BAFNA PHARMACEUTICALS Limited | 1.76 | 1.76 | 35.86 | 51.38 | 4.89 | 2.57 | Standalone |
| Trident Lifeline Ltd | 11.35 | 11.35 | 57.16 | 25.29 | 19.85 | 5.04 | Standalone |
Notes:
Asston Pharmaceuticals IPO Reviews, analysis and views by popular members. Read Asston Pharmaceuticals Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
Useful Articles
RHP